206 related articles for article (PubMed ID: 32793911)
1. Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity.
Hoffmann M; Hofmann-Winkler H; Smith JC; Krüger N; Sørensen LK; Søgaard OS; Hasselstrøm JB; Winkler M; Hempel T; Raich L; Olsson S; Yamazoe T; Yamatsuta K; Mizuno H; Ludwig S; Noé F; Sheltzer JM; Kjolby M; Pöhlmann S
bioRxiv; 2020 Aug; ():. PubMed ID: 32793911
[TBL] [Abstract][Full Text] [Related]
2. Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity.
Hoffmann M; Hofmann-Winkler H; Smith JC; Krüger N; Arora P; Sørensen LK; Søgaard OS; Hasselstrøm JB; Winkler M; Hempel T; Raich L; Olsson S; Danov O; Jonigk D; Yamazoe T; Yamatsuta K; Mizuno H; Ludwig S; Noé F; Kjolby M; Braun A; Sheltzer JM; Pöhlmann S
EBioMedicine; 2021 Mar; 65():103255. PubMed ID: 33676899
[TBL] [Abstract][Full Text] [Related]
3. Structural Basis of Covalent Inhibitory Mechanism of TMPRSS2-Related Serine Proteases by Camostat.
Sun G; Sui Y; Zhou Y; Ya J; Yuan C; Jiang L; Huang M
J Virol; 2021 Sep; 95(19):e0086121. PubMed ID: 34160253
[TBL] [Abstract][Full Text] [Related]
4. Semi-Mechanistic Pharmacokinetic-Pharmacodynamic Model of Camostat Mesylate-Predicted Efficacy against SARS-CoV-2 in COVID-19.
Kosinsky Y; Peskov K; Stanski DR; Wetmore D; Vinetz J
Microbiol Spectr; 2022 Apr; 10(2):e0216721. PubMed ID: 35412356
[TBL] [Abstract][Full Text] [Related]
5. Synergistic Block of SARS-CoV-2 Infection by Combined Drug Inhibition of the Host Entry Factors PIKfyve Kinase and TMPRSS2 Protease.
Kreutzberger AJB; Sanyal A; Ojha R; Pyle JD; Vapalahti O; Balistreri G; Kirchhausen T
J Virol; 2021 Oct; 95(21):e0097521. PubMed ID: 34406858
[TBL] [Abstract][Full Text] [Related]
6. Camostat mesylate against SARS-CoV-2 and COVID-19-Rationale, dosing and safety.
Breining P; Frølund AL; Højen JF; Gunst JD; Staerke NB; Saedder E; Cases-Thomas M; Little P; Nielsen LP; Søgaard OS; Kjolby M
Basic Clin Pharmacol Toxicol; 2021 Feb; 128(2):204-212. PubMed ID: 33176395
[TBL] [Abstract][Full Text] [Related]
7. Low risk of the TMPRSS2 inhibitor camostat mesylate and its metabolite GBPA to act as perpetrators of drug-drug interactions.
Weiss J; Bajraktari-Sylejmani G; Haefeli WE
Chem Biol Interact; 2021 Apr; 338():109428. PubMed ID: 33647240
[TBL] [Abstract][Full Text] [Related]
8. Structural insights and inhibition mechanism of TMPRSS2 by experimentally known inhibitors Camostat mesylate, Nafamostat and Bromhexine hydrochloride to control SARS-coronavirus-2: A molecular modeling approach.
Sonawane KD; Barale SS; Dhanavade MJ; Waghmare SR; Nadaf NH; Kamble SA; Mohammed AA; Makandar AM; Fandilolu PM; Dound AS; Naik NM; More VB
Inform Med Unlocked; 2021; 24():100597. PubMed ID: 34075338
[TBL] [Abstract][Full Text] [Related]
9. A phase I study of high dose camostat mesylate in healthy adults provides a rationale to repurpose the TMPRSS2 inhibitor for the treatment of COVID-19.
Kitagawa J; Arai H; Iida H; Mukai J; Furukawa K; Ohtsu S; Nakade S; Hikima T; Haranaka M; Uemura N
Clin Transl Sci; 2021 Sep; 14(5):1967-1976. PubMed ID: 33982445
[TBL] [Abstract][Full Text] [Related]
10. Middle East respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2.
Shirato K; Kawase M; Matsuyama S
J Virol; 2013 Dec; 87(23):12552-61. PubMed ID: 24027332
[TBL] [Abstract][Full Text] [Related]
11. Synergistic block of SARS-CoV-2 infection by combined drug inhibition of the host entry factors PIKfyve kinase and TMPRSS2 protease.
Kreutzberger AJB; Sanyal A; Ojha R; Pyle JD; Vapalahti O; Balistreri G; Kirchhausen T
bioRxiv; 2021 Aug; ():. PubMed ID: 34100014
[TBL] [Abstract][Full Text] [Related]
12. Structural modeling and analysis of the SARS-CoV-2 cell entry inhibitor camostat bound to the trypsin-like protease TMPRSS2.
Escalante DE; Ferguson DM
Med Chem Res; 2021; 30(2):399-409. PubMed ID: 33564221
[TBL] [Abstract][Full Text] [Related]
13. Spontaneous binding of potential COVID-19 drugs (Camostat and Nafamostat) to human serine protease TMPRSS2.
Zhu H; Du W; Song M; Liu Q; Herrmann A; Huang Q
Comput Struct Biotechnol J; 2021; 19():467-476. PubMed ID: 33505639
[TBL] [Abstract][Full Text] [Related]
14. Alpha 1 Antitrypsin is an Inhibitor of the SARS-CoV-2-Priming Protease TMPRSS2.
Azouz NP; Klingler AM; Callahan V; Akhrymuk IV; Elez K; Raich L; Henry BM; Benoit JL; Benoit SW; Noé F; Kehn-Hall K; Rothenberg ME
Pathog Immun; 2021; 6(1):55-74. PubMed ID: 33969249
[TBL] [Abstract][Full Text] [Related]
15. Combinations of Host- and Virus-Targeting Antiviral Drugs Confer Synergistic Suppression of SARS-CoV-2.
Wagoner J; Herring S; Hsiang TY; Ianevski A; Biering SB; Xu S; Hoffmann M; Pöhlmann S; Gale M; Aittokallio T; Schiffer JT; White JM; Polyak SJ
Microbiol Spectr; 2022 Oct; 10(5):e0333122. PubMed ID: 36190406
[TBL] [Abstract][Full Text] [Related]
16. Molecular mechanism of inhibiting the SARS-CoV-2 cell entry facilitator TMPRSS2 with camostat and nafamostat.
Hempel T; Raich L; Olsson S; Azouz NP; Klingler AM; Hoffmann M; Pöhlmann S; Rothenberg ME; Noé F
Chem Sci; 2021 Jan; 12(3):983-992. PubMed ID: 35382133
[TBL] [Abstract][Full Text] [Related]
17.
Salleh MZ; Deris ZZ
Life (Basel); 2022 Feb; 12(2):. PubMed ID: 35207518
[TBL] [Abstract][Full Text] [Related]
18. An Enzymatic TMPRSS2 Assay for Assessment of Clinical Candidates and Discovery of Inhibitors as Potential Treatment of COVID-19.
Shrimp JH; Kales SC; Sanderson PE; Simeonov A; Shen M; Hall MD
bioRxiv; 2020 Aug; ():. PubMed ID: 32596694
[TBL] [Abstract][Full Text] [Related]
19. A Double-Blind, Randomized, Placebo-Controlled, Phase II Clinical Study To Evaluate the Efficacy and Safety of Camostat Mesylate (DWJ1248) in Adult Patients with Mild to Moderate COVID-19.
Kim YS; Jeon SH; Kim J; Koh JH; Ra SW; Kim JW; Kim Y; Kim CK; Shin YC; Kang BD; Kang SJ; Park CH; Lee B; Lee JY; Lee CH; Choi JP; Kim JY; Yu SN; Peck KR; Kim SH; Heo JY; Kim HA; Park HJ; Choi J; Han J; Kim J; Kim HJ; Han SH; Yoon A; Park M; Park S; Kim Y; Jung M; Oh MD
Antimicrob Agents Chemother; 2023 Jan; 67(1):e0045222. PubMed ID: 36515544
[TBL] [Abstract][Full Text] [Related]
20. Virtual Screening of Natural Products against Type II Transmembrane Serine Protease (TMPRSS2), the Priming Agent of Coronavirus 2 (SARS-CoV-2).
Rahman N; Basharat Z; Yousuf M; Castaldo G; Rastrelli L; Khan H
Molecules; 2020 May; 25(10):. PubMed ID: 32408547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
